AP2M1 and colorectal carcinoma: Several epigenetically deregulated genes associated with therapy resistance in CTCs were identified, particularly AP2M1. Loss of methylation in CTCs could be a potential non-invasive biomarker in CRC patients for monitoring the effectiveness of treatment and the development of resistance, which should be evaluated and confirmed in future clinical studies.